epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
Avasopasem
avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Breyna

budesonide/ formoterol inhaled

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  MDI: 80 mcg/4.5 mcg per actuation, 160 mcg/4.5 mcg per actuation

COPD, maintenance tx

[2 puffs (160 mcg/4.5 mcg per actuation) inhaled bid]
Max: 640 mcg/18 mcg/day; Info: search 'gold' for epocrates COPD GOLD decision tools

asthma, maintenance tx

[2 puffs (80 mcg/4.5 mcg or 160 mcg/4.5 mcg per actuation) inhaled bid]
Start: varies by disease severity and current asthma tx, may incr. dose after 1-2wk; Max: 640 mcg/18 mcg/day; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools

asthma, moderate-severe persistent (off-label)

[single-inhaler maintenance and reliever tx (SMART)]
Dose: 1-2 puffs inhaled qd-bid, then 1-2 puffs inhaled q4h prn; Start: varies by disease severity and current asthma tx; Max: 12 puffs/day; 54 mcg/day formoterol; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools

renal dosing

[not defined]
renal impairment: not defined
HD/PD: not defined

hepatic dosing

[see below]
hepatic impairment: not defined, caution advised

Peds Dosing .

Dosage forms:  MDI: 80 mcg/4.5 mcg per actuation, 160 mcg/4.5 mcg per actuation

asthma, maintenance tx

[6-11 yo]
Dose: 2 puffs (80 mcg/4.5 mcg per actuation) inhaled bid; Max: 320 mcg/18 mcg/day; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools
[12 yo and older]
Dose: 2 puffs (80 mcg/4.5 mcg or 160 mcg/4.5 mcg per actuation) inhaled bid; Start: varies by disease severity and current asthma tx, may incr. dose after 1-2wk; Max: 640 mcg/18 mcg/day; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools

asthma, moderate-severe persistent (off-label)

[single-inhaler maintenance and reliever tx (SMART), 5-11 yo]
Dose: 1-2 puff inhaled qd-bid, then 1-2 puffs inhaled q4h prn; Start: varies by disease severity and current asthma tx; Max: 8 puffs/day; 36 mcg/day formoterol; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools
[single-inhaler maintenance and reliever tx (SMART), 12 yo and older]
Dose: 1-2 puffs inhaled qd-bid, then 1-2 puffs inhaled q4h prn; Start: varies by disease severity and current asthma tx; Max: 12 puffs/day; 54 mcg/day formoterol; Info: taper to lowest effective dose; search 'asthma' for epocrates Asthma Long-Term Management NIH/NHLBI decision tools

renal dosing

[not defined]
renal impairment: not defined
HD/PD: not defined

hepatic dosing

[see below]
hepatic impairment: not defined, caution advised

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@7f98f4bd
  • hypersensitivity to drug or ingredient
  • status asthmaticus
  • asthma, acute
  • bronchospasm, acute
  • COPD, acute deteriorating
  • caution: hypersensitivity to corticosteroids
  • caution: peds patients
  • caution: adolescent patients
  • caution: MAO inhibitor use within 14 days
  • caution: TCA use within 14 days
  • caution: electrolyte abnormalities
  • caution: long QT syndrome, congenital
  • caution: QT prolongation
  • caution: QT prolongation family history
  • caution: torsades de pointes history
  • caution: arrhythmia
  • caution: bradycardia
  • caution: MI, recent
  • caution: CHF
  • caution: cardiovascular disease
  • caution: patients unusually responsive to sympathomimetic amines
  • caution: diabetes mellitus
  • caution: ketoacidosis
  • caution: seizure disorder
  • caution: hyperthyroidism
  • caution: labor and delivery
  • caution: hepatic impairment
  • caution: long-term systemic corticosteroid use, recent
  • caution: immunosuppressed patients
  • caution: infection, active
  • caution: TB infection, active
  • caution: TB infection, latent
  • caution: measles exposure
  • caution: varicella exposure
  • caution: osteoporosis
  • caution: osteoporosis risk
  • caution: cataract
  • caution: glaucoma
  • caution: glaucoma risk
  • caution: ocular HSV

Drug Interactions .

Overview

budesonide inhaled

corticosteroid inhaled

Interaction Characteristics:
  • CYP3A4 substrate
  • immunomodulatory effects
  • interferes w/ ACTH analog test

formoterol inhaled

beta-2 agonist

Interaction Characteristics:
  • hypertensive effects
  • hypokalemia
  • prolongs QT interval (conditional)
  • tachycardia

Contraindicated

  • desmopressin
  • Breyna (budesonide/ formoterol inhaled)
    +
    desmopressin
    2 interactions

    Contraindicated

    budesonide inhaled + desmopressin

    DESMOPRESSIN INJECTABLE: contraindicated; OTHER DESMOPRESSIN ROUTES: monitor sodium: combo may incr. risk of hyponatremia, including life-threatening (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pimozide
  • Breyna (budesonide/ formoterol inhaled)
    +
    pimozide
    1 interaction

    Contraindicated

    formoterol inhaled + pimozide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • thioridazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    thioridazine
    1 interaction

    Contraindicated

    formoterol inhaled + thioridazine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

  • albuterol
  • Breyna (budesonide/ formoterol inhaled)
    +
    albuterol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + albuterol

    consider alternative if long-term use; otherwise, monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia (additive effects, duplicate therapy)

  • arformoterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    arformoterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + arformoterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse events or fatalities (additive effects, duplicate long-acting beta 2 agonist tx)

  • arsenic trioxide
  • Breyna (budesonide/ formoterol inhaled)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + arsenic trioxide

    use alternative or monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • bedaquiline
  • Breyna (budesonide/ formoterol inhaled)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + bedaquiline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • budesonide inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    budesonide inhaled
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + budesonide inhaled

    avoid combo: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • carvedilol
  • Breyna (budesonide/ formoterol inhaled)
    +
    carvedilol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + carvedilol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • cisapride
  • Breyna (budesonide/ formoterol inhaled)
    +
    cisapride
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + cisapride

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cladribine oral
  • Breyna (budesonide/ formoterol inhaled)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + cladribine oral

    use alternative: combo may incr. risk of serious infection (additive effects)

  • cobicistat
  • Breyna (budesonide/ formoterol inhaled)
    +
    cobicistat
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + cobicistat

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • cocaine
  • Breyna (budesonide/ formoterol inhaled)
    +
    cocaine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + cocaine

    use alternative or monitor BP, HR, ECG: combo may incr. risk of severe vasoconstriction, HTN, tachycardia, arrhythmias (additive effects)

  • crizotinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + crizotinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • darunavir
  • Breyna (budesonide/ formoterol inhaled)
    +
    darunavir
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + darunavir

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • domperidone
  • Breyna (budesonide/ formoterol inhaled)
    +
    domperidone
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + domperidone

    use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dronabinol
  • Breyna (budesonide/ formoterol inhaled)
    +
    dronabinol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + dronabinol

    avoid combo: combo may incr. risk of HTN, tachycardia (additive effects)

  • dronedarone
  • Breyna (budesonide/ formoterol inhaled)
    +
    dronedarone
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + dronedarone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ephedra
  • Breyna (budesonide/ formoterol inhaled)
    +
    ephedra
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + ephedra

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epinephrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    epinephrine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + epinephrine

    use alternative or monitor BP, HR, potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epinephrine inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    epinephrine inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN (including hypertensive crisis), tachycardia, other cardiovascular adverse effects (additive effects)

  • fexinidazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + fexinidazole

    if possible, do not initiate fexinidazole until 5 half-lives after formoterol D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • formoterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    formoterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + formoterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse events or fatalities (additive effects, duplicate long-acting beta 2 agonist tx)

  • fosfomycin injection
  • Breyna (budesonide/ formoterol inhaled)
    +
    fosfomycin injection
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + fosfomycin injection

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • furosemide
  • Breyna (budesonide/ formoterol inhaled)
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + furosemide

    use alternative or monitor BP, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of hypokalemia, ECG changes (antagonistic effects; additive effects)

  • hydroxychloroquine
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydroxychloroquine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + hydroxychloroquine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • labetalol
  • Breyna (budesonide/ formoterol inhaled)
    +
    labetalol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + labetalol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • landiolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    landiolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + landiolol

    use alternative or monitor HR, BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • lefamulin
  • Breyna (budesonide/ formoterol inhaled)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + lefamulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lonafarnib
  • Breyna (budesonide/ formoterol inhaled)
    +
    lonafarnib
    2 interactions

    Avoid/Use Alternative

    formoterol inhaled + lonafarnib

    use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + lonafarnib

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • lopinavir/ritonavir
  • Breyna (budesonide/ formoterol inhaled)
    +
    lopinavir/ ritonavir
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + lopinavir/ ritonavir

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • midodrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    midodrine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

  • mobocertinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + mobocertinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • nadolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    nadolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + nadolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • natalizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    natalizumab
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + natalizumab

    avoid combo: combo may incr. risk of serious infection (additive effects)

  • nebivolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    nebivolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + nebivolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • olodaterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    olodaterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + olodaterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse events or fatalities (additive effects, duplicate long-acting beta 2 agonist tx)

  • phenelzine
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenelzine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + phenelzine

    consider alternative or monitor BP, HR during and x2wk after phenelzine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • pimecrolimus topical
  • Breyna (budesonide/ formoterol inhaled)
    +
    pimecrolimus topical
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + pimecrolimus topical

    avoid combo: combo may incr. risk of serious infection (additive effects)

  • pindolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    pindolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + pindolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • propranolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    propranolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + propranolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • quizartinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    quizartinib
    2 interactions

    Avoid/Use Alternative

    formoterol inhaled + quizartinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + quizartinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ritonavir
  • Breyna (budesonide/ formoterol inhaled)
    +
    ritonavir
    1 interaction

    Avoid/Use Alternative

    budesonide inhaled + ritonavir

    consider alternative (incl. beclomethasone), especially if long-term corticosteroid use; lower risk w/ nirmatrelvir/ritonavir tx: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • salmeterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    salmeterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + salmeterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • sotalol
  • Breyna (budesonide/ formoterol inhaled)
    +
    sotalol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + sotalol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • timolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    timolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + timolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • toremifene
  • Breyna (budesonide/ formoterol inhaled)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + toremifene

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vandetanib
  • Breyna (budesonide/ formoterol inhaled)
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + vandetanib

    use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • vilanterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    vilanterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + vilanterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • ziprasidone
  • Breyna (budesonide/ formoterol inhaled)
    +
    ziprasidone
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + ziprasidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

  • abiraterone acetate
  • Breyna (budesonide/ formoterol inhaled)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + abiraterone acetate

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • acebutolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + acebutolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • acetazolamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    acetazolamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + acetazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • adagrasib
  • Breyna (budesonide/ formoterol inhaled)
    +
    adagrasib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + adagrasib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + adagrasib

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • albuterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + albuterol inhaled

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • aliskiren
  • Breyna (budesonide/ formoterol inhaled)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • almotriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aloe
  • Breyna (budesonide/ formoterol inhaled)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aloe

    monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

  • amiloride
  • Breyna (budesonide/ formoterol inhaled)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • aminophylline
  • Breyna (budesonide/ formoterol inhaled)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aminophylline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • amiodarone
  • Breyna (budesonide/ formoterol inhaled)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amiodarone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • amitriptyline
  • Breyna (budesonide/ formoterol inhaled)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amitriptyline

    monitor BP, HR during and x2wk after amitriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • amlodipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amoxapine
  • Breyna (budesonide/ formoterol inhaled)
    +
    amoxapine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amoxapine

    monitor BP, HR during and x2wk after amoxapine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • amphetamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • amphotericin
  • Breyna (budesonide/ formoterol inhaled)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amphotericin

    monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

  • anagrelide
  • Breyna (budesonide/ formoterol inhaled)
    +
    anagrelide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + anagrelide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • angiotensin II
  • Breyna (budesonide/ formoterol inhaled)
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

  • apalutamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    apalutamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + apalutamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • apomorphine
  • Breyna (budesonide/ formoterol inhaled)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + apomorphine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • aprocitentan
  • Breyna (budesonide/ formoterol inhaled)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • armodafinil
  • Breyna (budesonide/ formoterol inhaled)
    +
    armodafinil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + armodafinil

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • artemether/lumefantrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + artemether/ lumefantrine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asciminib
  • Breyna (budesonide/ formoterol inhaled)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asenapine
  • Breyna (budesonide/ formoterol inhaled)
    +
    asenapine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + asenapine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asparaginase
  • Breyna (budesonide/ formoterol inhaled)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + asparaginase

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • atenolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atenolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • atogepant
  • Breyna (budesonide/ formoterol inhaled)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atomoxetine
  • Breyna (budesonide/ formoterol inhaled)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atomoxetine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • atropine
  • Breyna (budesonide/ formoterol inhaled)
    +
    atropine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atropine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • atropine ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    atropine ophthalmic
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • axitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • azilsartan medoxomil
  • Breyna (budesonide/ formoterol inhaled)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • azithromycin
  • Breyna (budesonide/ formoterol inhaled)
    +
    azithromycin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + azithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • benazepril
  • Breyna (budesonide/ formoterol inhaled)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benzphetamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + benzphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • benztropine
  • Breyna (budesonide/ formoterol inhaled)
    +
    benztropine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + benztropine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • betamethasone
  • Breyna (budesonide/ formoterol inhaled)
    +
    betamethasone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + betamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + betamethasone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • betaxolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + betaxolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • bevacizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bismuth subsalicylate
  • Breyna (budesonide/ formoterol inhaled)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • bisoprolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bisoprolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • brigatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + brigatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • budesonide
  • Breyna (budesonide/ formoterol inhaled)
    +
    budesonide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + budesonide

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + budesonide

    caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • bumetanide
  • Breyna (budesonide/ formoterol inhaled)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bumetanide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • bupropion
  • Breyna (budesonide/ formoterol inhaled)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bupropion

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • cabozantinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cabozantinib

    monitor BP, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • caffeine
  • Breyna (budesonide/ formoterol inhaled)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + caffeine

    monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects)

  • caffeine citrate
  • Breyna (budesonide/ formoterol inhaled)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + caffeine citrate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • candesartan cilexetil
  • Breyna (budesonide/ formoterol inhaled)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cannabis
  • Breyna (budesonide/ formoterol inhaled)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cannabis

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • captopril
  • Breyna (budesonide/ formoterol inhaled)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carfilzomib
  • Breyna (budesonide/ formoterol inhaled)
    +
    carfilzomib
    2 interactions

    Monitor/Modify Tx

    budesonide inhaled + carfilzomib

    consider antiviral prophylaxis: combo may incr. risk of serious infection (additive effects)

    formoterol inhaled + carfilzomib

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • celecoxib
  • Breyna (budesonide/ formoterol inhaled)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ceritinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ceritinib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + ceritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + ceritinib

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • cetuximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    cetuximab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cetuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chloroquine
  • Breyna (budesonide/ formoterol inhaled)
    +
    chloroquine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + chloroquine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • chlorothiazide
  • Breyna (budesonide/ formoterol inhaled)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + chlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • chlorthalidone
  • Breyna (budesonide/ formoterol inhaled)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + chlorthalidone

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • cisplatin
  • Breyna (budesonide/ formoterol inhaled)
    +
    cisplatin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + cisplatin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + cisplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • citalopram
  • Breyna (budesonide/ formoterol inhaled)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + citalopram

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clarithromycin
  • Breyna (budesonide/ formoterol inhaled)
    +
    clarithromycin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + clarithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + clarithromycin

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • clevidipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clofazimine
  • Breyna (budesonide/ formoterol inhaled)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clofazimine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clomipramine
  • Breyna (budesonide/ formoterol inhaled)
    +
    clomipramine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clomipramine

    monitor BP, HR during and x2wk after clomipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • clonidine
  • Breyna (budesonide/ formoterol inhaled)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • copanlisib
  • Breyna (budesonide/ formoterol inhaled)
    +
    copanlisib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

    Caution Advised

    budesonide inhaled + copanlisib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • corticotropin
  • Breyna (budesonide/ formoterol inhaled)
    +
    corticotropin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + corticotropin

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + corticotropin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cortisone
  • Breyna (budesonide/ formoterol inhaled)
    +
    cortisone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + cortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + cortisone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • cosyntropin
  • Breyna (budesonide/ formoterol inhaled)
    +
    cosyntropin
    1 interaction

    Monitor/Modify Tx

    budesonide inhaled + cosyntropin

    hold budesonide on day of test: combo may interfere with test results (budesonide may alter plasma cortisol levels)

  • cyclosporine
  • Breyna (budesonide/ formoterol inhaled)
    +
    cyclosporine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + cyclosporine

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + cyclosporine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • danazol
  • Breyna (budesonide/ formoterol inhaled)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • darbepoetin alfa
  • Breyna (budesonide/ formoterol inhaled)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • decitabine
  • Breyna (budesonide/ formoterol inhaled)
    +
    decitabine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + decitabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deflazacort
  • Breyna (budesonide/ formoterol inhaled)
    +
    deflazacort
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + deflazacort

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + deflazacort

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • degarelix
  • Breyna (budesonide/ formoterol inhaled)
    +
    degarelix
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + degarelix

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Breyna (budesonide/ formoterol inhaled)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + desflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desipramine
  • Breyna (budesonide/ formoterol inhaled)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + desipramine

    monitor ECG, BP, HR during and x2wk after desipramine D/C: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • desvenlafaxine
  • Breyna (budesonide/ formoterol inhaled)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + desvenlafaxine

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • dexamethasone
  • Breyna (budesonide/ formoterol inhaled)
    +
    dexamethasone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + dexamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + dexamethasone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • dexmedetomidine
  • Breyna (budesonide/ formoterol inhaled)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexmedetomidine

    monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine injection
  • Breyna (budesonide/ formoterol inhaled)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexmedetomidine injection

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmethylphenidate
  • Breyna (budesonide/ formoterol inhaled)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexmethylphenidate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dextroamphetamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dextroamphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dichlorphenamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    dichlorphenamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dichlorphenamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • diclofenac
  • Breyna (budesonide/ formoterol inhaled)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac topical
  • Breyna (budesonide/ formoterol inhaled)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dicyclomine
  • Breyna (budesonide/ formoterol inhaled)
    +
    dicyclomine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dicyclomine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • diethylpropion
  • Breyna (budesonide/ formoterol inhaled)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diethylpropion

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • diflunisal
  • Breyna (budesonide/ formoterol inhaled)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • digoxin
  • Breyna (budesonide/ formoterol inhaled)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + digoxin

    monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

  • dihydroergotamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dihydroergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • diltiazem
  • Breyna (budesonide/ formoterol inhaled)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dinutuximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    dinutuximab
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + dinutuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + dinutuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • disopyramide
  • Breyna (budesonide/ formoterol inhaled)
    +
    disopyramide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + disopyramide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dobutamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    dobutamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dobutamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dofetilide
  • Breyna (budesonide/ formoterol inhaled)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dofetilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • donepezil
  • Breyna (budesonide/ formoterol inhaled)
    +
    donepezil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + donepezil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dopamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    dopamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dopamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dordaviprone
  • Breyna (budesonide/ formoterol inhaled)
    +
    dordaviprone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dordaviprone

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • doxapram
  • Breyna (budesonide/ formoterol inhaled)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + doxapram

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • doxazosin
  • Breyna (budesonide/ formoterol inhaled)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • doxepin
  • Breyna (budesonide/ formoterol inhaled)
    +
    doxepin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + doxepin

    monitor BP, HR during and x2wk after doxepin D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • droperidol
  • Breyna (budesonide/ formoterol inhaled)
    +
    droperidol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + droperidol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • droxidopa
  • Breyna (budesonide/ formoterol inhaled)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

  • eletriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • emapalumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    emapalumab
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + emapalumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + emapalumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • enalapril
  • Breyna (budesonide/ formoterol inhaled)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Breyna (budesonide/ formoterol inhaled)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • encorafenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    encorafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + encorafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ephedrine injection
  • Breyna (budesonide/ formoterol inhaled)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ephedrine injection

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • ephedrine oral
  • Breyna (budesonide/ formoterol inhaled)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ephedrine oral

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epirubicin
  • Breyna (budesonide/ formoterol inhaled)
    +
    epirubicin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + epirubicin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + epirubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • eplerenone
  • Breyna (budesonide/ formoterol inhaled)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eplerenone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epoetin alfa
  • Breyna (budesonide/ formoterol inhaled)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eptinezumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    eptinezumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • erenumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    erenumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ergotamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • eribulin
  • Breyna (budesonide/ formoterol inhaled)
    +
    eribulin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + eribulin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + eribulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • erythromycin
  • Breyna (budesonide/ formoterol inhaled)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + erythromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • esketamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + esketamine

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • esmolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + esmolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • estetrol (contraceptive)
  • Breyna (budesonide/ formoterol inhaled)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • estradiol (contraceptive)
  • Breyna (budesonide/ formoterol inhaled)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ethacrynic acid
  • Breyna (budesonide/ formoterol inhaled)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ethacrynic acid

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • ethanol (alcoholic beverage)
  • Breyna (budesonide/ formoterol inhaled)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • ethinyl estradiol (contraceptive)
  • Breyna (budesonide/ formoterol inhaled)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etodolac
  • Breyna (budesonide/ formoterol inhaled)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etrasimod
  • Breyna (budesonide/ formoterol inhaled)
    +
    etrasimod
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + etrasimod

    caution advised during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • everolimus
  • Breyna (budesonide/ formoterol inhaled)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    budesonide inhaled + everolimus

    admin. PCP prophylaxis: combo may incr. risk of serious infection (additive effects)

  • felodipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + felodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenfluramine
  • Breyna (budesonide/ formoterol inhaled)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenoldopam
  • Breyna (budesonide/ formoterol inhaled)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Breyna (budesonide/ formoterol inhaled)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fingolimod
  • Breyna (budesonide/ formoterol inhaled)
    +
    fingolimod
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + fingolimod

    caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • flecainide
  • Breyna (budesonide/ formoterol inhaled)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + flecainide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fludrocortisone
  • Breyna (budesonide/ formoterol inhaled)
    +
    fludrocortisone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + fludrocortisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + fludrocortisone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluorouracil
  • Breyna (budesonide/ formoterol inhaled)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fluorouracil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flurbiprofen
  • Breyna (budesonide/ formoterol inhaled)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • foscarnet
  • Breyna (budesonide/ formoterol inhaled)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + foscarnet

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • fosinopril
  • Breyna (budesonide/ formoterol inhaled)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fostamatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fremanezumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    fremanezumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • frovatriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    fruquintinib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    Caution Advised

    budesonide inhaled + fruquintinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • galcanezumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    galcanezumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • gilteritinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + gilteritinib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • glasdegib
  • Breyna (budesonide/ formoterol inhaled)
    +
    glasdegib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + glasdegib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • glycopyrrolate
  • Breyna (budesonide/ formoterol inhaled)
    +
    glycopyrrolate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + glycopyrrolate

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • goserelin
  • Breyna (budesonide/ formoterol inhaled)
    +
    goserelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + goserelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • guanfacine
  • Breyna (budesonide/ formoterol inhaled)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • haloperidol
  • Breyna (budesonide/ formoterol inhaled)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + haloperidol

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Breyna (budesonide/ formoterol inhaled)
    +
    histrelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + histrelin

    consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hoodia
  • Breyna (budesonide/ formoterol inhaled)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hoodia

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • hydralazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydrochlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • hydrocortisone
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydrocortisone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + hydrocortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + hydrocortisone

    caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • hydroxocobalamin IV
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydroxyzine
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydroxyzine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydroxyzine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • hyoscyamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    hyoscyamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hyoscyamine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • ibrutinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ibrutinib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + ibrutinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + ibrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ibuprofen
  • Breyna (budesonide/ formoterol inhaled)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibutilide
  • Breyna (budesonide/ formoterol inhaled)
    +
    ibutilide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ibutilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • imipramine
  • Breyna (budesonide/ formoterol inhaled)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + imipramine

    monitor BP, HR during and x2wk after imipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • indapamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + indapamide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • indomethacin
  • Breyna (budesonide/ formoterol inhaled)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • inotuzumab ozogamicin
  • Breyna (budesonide/ formoterol inhaled)
    +
    inotuzumab ozogamicin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + inotuzumab ozogamicin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + inotuzumab ozogamicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • insulin
  • Breyna (budesonide/ formoterol inhaled)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + insulin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • irbesartan
  • Breyna (budesonide/ formoterol inhaled)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • isocarboxazid
  • Breyna (budesonide/ formoterol inhaled)
    +
    isocarboxazid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isocarboxazid

    monitor BP, HR during and x2wk after isocarboxazid D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • isoflurane
  • Breyna (budesonide/ formoterol inhaled)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoproterenol
  • Breyna (budesonide/ formoterol inhaled)
    +
    isoproterenol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isoproterenol

    monitor potassium, HR: combo may incr. risk of hypokalemia, tachycardia (additive effects)

  • isradipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ivosidenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ivosidenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ivosidenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ketamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ketamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other sympathomimetic adverse effects (additive effects)

  • ketoprofen
  • Breyna (budesonide/ formoterol inhaled)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketorolac
  • Breyna (budesonide/ formoterol inhaled)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lanreotide
  • Breyna (budesonide/ formoterol inhaled)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leflunomide
  • Breyna (budesonide/ formoterol inhaled)
    +
    leflunomide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + leflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + leflunomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lenalidomide
  • Breyna (budesonide/ formoterol inhaled)
    +
    lenalidomide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + lenalidomide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + lenalidomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lenvatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leuprolide
  • Breyna (budesonide/ formoterol inhaled)
    +
    leuprolide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + leuprolide

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levalbuterol inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levalbuterol inhaled

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • levofloxacin
  • Breyna (budesonide/ formoterol inhaled)
    +
    levofloxacin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levoketoconazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    levoketoconazole
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + levoketoconazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + levoketoconazole

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • levomilnacipran
  • Breyna (budesonide/ formoterol inhaled)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levomilnacipran

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • levothyroxine
  • Breyna (budesonide/ formoterol inhaled)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levothyroxine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • licorice
  • Breyna (budesonide/ formoterol inhaled)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + licorice

    monitor BP, potassium w/ large amounts of licorice: combo may incr. risk of HTN, hypokalemia (additive effects)

  • lifileucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lifileucel

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • linezolid
  • Breyna (budesonide/ formoterol inhaled)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + linezolid

    monitor BP, HR during and x2wk after linezolid D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • liothyronine
  • Breyna (budesonide/ formoterol inhaled)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + liothyronine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • liraglutide
  • Breyna (budesonide/ formoterol inhaled)
    +
    liraglutide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + liraglutide

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • lisdexamfetamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lisdexamfetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • lisinopril
  • Breyna (budesonide/ formoterol inhaled)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lofexidine
  • Breyna (budesonide/ formoterol inhaled)
    +
    lofexidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lofexidine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lorlatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    lorlatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lorlatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • losartan
  • Breyna (budesonide/ formoterol inhaled)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lumacaftor/ivacaftor
  • Breyna (budesonide/ formoterol inhaled)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lumacaftor/ ivacaftor

    monitor BP: combo may incr. risk of HTN (additive effects)

  • luspatercept
  • Breyna (budesonide/ formoterol inhaled)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • macimorelin
  • Breyna (budesonide/ formoterol inhaled)
    +
    macimorelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + macimorelin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium citrate
  • Breyna (budesonide/ formoterol inhaled)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + magnesium citrate

    monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium salicylate
  • Breyna (budesonide/ formoterol inhaled)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • mannitol
  • Breyna (budesonide/ formoterol inhaled)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + mannitol

    monitor potassium, cardiac fxn: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • meclofenamate
  • Breyna (budesonide/ formoterol inhaled)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mefenamic acid
  • Breyna (budesonide/ formoterol inhaled)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

  • meloxicam
  • Breyna (budesonide/ formoterol inhaled)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methacholine inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    methacholine inhaled
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + methacholine inhaled

    hold ultra-LABA formoterol x48h before diagnostic test: combo may interfere with test results (antagonistic effects)

    Caution Advised

    budesonide inhaled + methacholine inhaled

    caution advised: combo may interfere with test results (antagonistic effects)

  • methadone
  • Breyna (budesonide/ formoterol inhaled)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methadone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • methamphetamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methamphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • methazolamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    methazolamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Breyna (budesonide/ formoterol inhaled)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methscopolamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    methscopolamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methscopolamine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • methyldopa
  • Breyna (budesonide/ formoterol inhaled)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Breyna (budesonide/ formoterol inhaled)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methylergonovine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • methylphenidate
  • Breyna (budesonide/ formoterol inhaled)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methylphenidate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • methylprednisolone
  • Breyna (budesonide/ formoterol inhaled)
    +
    methylprednisolone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + methylprednisolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + methylprednisolone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • methyltestosterone
  • Breyna (budesonide/ formoterol inhaled)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metoclopramide
  • Breyna (budesonide/ formoterol inhaled)
    +
    metoclopramide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metolazone
  • Breyna (budesonide/ formoterol inhaled)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + metolazone

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • metoprolol
  • Breyna (budesonide/ formoterol inhaled)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + metoprolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • metyrapone
  • Breyna (budesonide/ formoterol inhaled)
    +
    metyrapone
    1 interaction

    Monitor/Modify Tx

    budesonide inhaled + metyrapone

    D/C budesonide 5 half-lives before metyrapone test: combo may alter test results (antagonistic effects, exogenous corticosteroids may interfere with test)

  • mifepristone
  • Breyna (budesonide/ formoterol inhaled)
    +
    mifepristone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + mifepristone

    monitor potassium if daily mifepristone use: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + mifepristone

    caution advised w/in 14 days of daily mifepristone use: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • milnacipran
  • Breyna (budesonide/ formoterol inhaled)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + milnacipran

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • minoxidil
  • Breyna (budesonide/ formoterol inhaled)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Breyna (budesonide/ formoterol inhaled)
    +
    mirabegron
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mitomycin
  • Breyna (budesonide/ formoterol inhaled)
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    budesonide inhaled + mitomycin

    caution advised; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of serious infection (additive effects)

  • modafinil
  • Breyna (budesonide/ formoterol inhaled)
    +
    modafinil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + modafinil

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • moexipril
  • Breyna (budesonide/ formoterol inhaled)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • motixafortide
  • Breyna (budesonide/ formoterol inhaled)
    +
    motixafortide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + motixafortide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • moxifloxacin
  • Breyna (budesonide/ formoterol inhaled)
    +
    moxifloxacin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + moxifloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • nabumetone
  • Breyna (budesonide/ formoterol inhaled)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naproxen
  • Breyna (budesonide/ formoterol inhaled)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naratriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naxitamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • necitumumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + necitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • nicardipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nifedipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nifedipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nilotinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nilotinib

    monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • nimodipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nimodipine

    monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

  • niraparib
  • Breyna (budesonide/ formoterol inhaled)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Breyna (budesonide/ formoterol inhaled)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nisoldipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • norepinephrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + norepinephrine

    monitor BP, HR: combo may incr. risk of HTN, cardiovascular adverse effects (additive effects)

  • nortriptyline
  • Breyna (budesonide/ formoterol inhaled)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nortriptyline

    monitor BP, HR during and x2wk after nortriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • obinutuzumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    obinutuzumab
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

    Caution Advised

    budesonide inhaled + obinutuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • oliceridine
  • Breyna (budesonide/ formoterol inhaled)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oliceridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • olmesartan medoxomil
  • Breyna (budesonide/ formoterol inhaled)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ondansetron
  • Breyna (budesonide/ formoterol inhaled)
    +
    ondansetron
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ondansetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • orphenadrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    orphenadrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + orphenadrine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • osilodrostat
  • Breyna (budesonide/ formoterol inhaled)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + osilodrostat

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • osimertinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    osimertinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + osimertinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxaprozin
  • Breyna (budesonide/ formoterol inhaled)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxymetazoline nasal
  • Breyna (budesonide/ formoterol inhaled)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oxymetazoline nasal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • oxytocin
  • Breyna (budesonide/ formoterol inhaled)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Breyna (budesonide/ formoterol inhaled)
    +
    ozanimod
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + ozanimod

    monitor BP, HR during and x2wk after ozanimod D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    budesonide inhaled + ozanimod

    caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • pacritinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pacritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • paliperidone
  • Breyna (budesonide/ formoterol inhaled)
    +
    paliperidone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + paliperidone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • palonosetron
  • Breyna (budesonide/ formoterol inhaled)
    +
    palonosetron
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + palonosetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pamidronate
  • Breyna (budesonide/ formoterol inhaled)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pamidronate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • panitumumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    panitumumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + panitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pasireotide
  • Breyna (budesonide/ formoterol inhaled)
    +
    pasireotide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pasireotide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pazopanib
  • Breyna (budesonide/ formoterol inhaled)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pentamidine
  • Breyna (budesonide/ formoterol inhaled)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pentamidine

    monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • perindopril
  • Breyna (budesonide/ formoterol inhaled)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pexidartinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    pexidartinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pexidartinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phendimetrazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phendimetrazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenoxybenzamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Breyna (budesonide/ formoterol inhaled)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phentermine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phentolamine
  • Breyna (budesonide/ formoterol inhaled)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenylephrine injection
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine injection

    monitor BP, HR: combo may incr. risk of HTN, cardiovascular adverse effects (additive effects)

  • phenylephrine nasal
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine nasal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • phenylephrine ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenylephrine ophthalmic
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine ophthalmic

    monitor BP, HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenylephrine rectal
  • Breyna (budesonide/ formoterol inhaled)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine rectal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • piroxicam
  • Breyna (budesonide/ formoterol inhaled)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • polyethylene glycol
  • Breyna (budesonide/ formoterol inhaled)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + polyethylene glycol

    monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • polyethylene glycol/electrolytes
  • Breyna (budesonide/ formoterol inhaled)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + polyethylene glycol/ electrolytes

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • ponatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ponatinib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + ponatinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ponesimod
  • Breyna (budesonide/ formoterol inhaled)
    +
    ponesimod
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + ponesimod

    caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • posaconazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    posaconazole
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + posaconazole

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + posaconazole

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • pralsetinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    pralsetinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pralsetinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • prazosin
  • Breyna (budesonide/ formoterol inhaled)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Breyna (budesonide/ formoterol inhaled)
    +
    prednisolone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + prednisolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + prednisolone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • prednisone
  • Breyna (budesonide/ formoterol inhaled)
    +
    prednisone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + prednisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + prednisone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • procainamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    procainamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + procainamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • procarbazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    procarbazine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + procarbazine

    monitor BP, HR during and x2wk after procarbazine D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

    Caution Advised

    budesonide inhaled + procarbazine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • propafenone
  • Breyna (budesonide/ formoterol inhaled)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + propafenone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • protriptyline
  • Breyna (budesonide/ formoterol inhaled)
    +
    protriptyline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + protriptyline

    monitor BP, HR during and x2wk after protriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • pseudoephedrine
  • Breyna (budesonide/ formoterol inhaled)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pseudoephedrine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • quetiapine
  • Breyna (budesonide/ formoterol inhaled)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

  • quinapril
  • Breyna (budesonide/ formoterol inhaled)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • quinidine (antiarrhythmic)
  • Breyna (budesonide/ formoterol inhaled)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quinidine (antiarrhythmic)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Breyna (budesonide/ formoterol inhaled)
    +
    quinidine (CYP2D6 inhibitor)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinine
  • Breyna (budesonide/ formoterol inhaled)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quinine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ramipril
  • Breyna (budesonide/ formoterol inhaled)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rasagiline
  • Breyna (budesonide/ formoterol inhaled)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rasagiline

    monitor BP, HR during and x2wk after rasagiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • regorafenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    regorafenib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + regorafenib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • revumenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    revumenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + revumenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribociclib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ribociclib
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + ribociclib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + ribociclib

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • rimegepant
  • Breyna (budesonide/ formoterol inhaled)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ripretinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rizatriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • romidepsin
  • Breyna (budesonide/ formoterol inhaled)
    +
    romidepsin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + romidepsin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    budesonide inhaled + romidepsin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ropinirole
  • Breyna (budesonide/ formoterol inhaled)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ropinirole

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rotigotine transdermal
  • Breyna (budesonide/ formoterol inhaled)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rotigotine transdermal

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • rucaparib
  • Breyna (budesonide/ formoterol inhaled)
    +
    rucaparib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rucaparib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sacituzumab govitecan
  • Breyna (budesonide/ formoterol inhaled)
    +
    sacituzumab govitecan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sacituzumab govitecan

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • safinamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    safinamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + safinamide

    monitor BP, HR during and x2wk after safinamide D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • salsalate
  • Breyna (budesonide/ formoterol inhaled)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + salsalate

    monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

  • selegiline
  • Breyna (budesonide/ formoterol inhaled)
    +
    selegiline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selegiline

    monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • selegiline transdermal
  • Breyna (budesonide/ formoterol inhaled)
    +
    selegiline transdermal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selegiline transdermal

    monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • selinexor
  • Breyna (budesonide/ formoterol inhaled)
    +
    selinexor
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + selinexor

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + selinexor

    caution advised: combo may incr. risk of serious infection (additive effects)

  • selpercatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selpercatinib

    monitor BP, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • sevoflurane
  • Breyna (budesonide/ formoterol inhaled)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sevoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • siponimod
  • Breyna (budesonide/ formoterol inhaled)
    +
    siponimod
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + siponimod

    caution advised during and x3-4wk after siponimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • sirolimus albumin-bound
  • Breyna (budesonide/ formoterol inhaled)
    +
    sirolimus albumin-bound
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + sirolimus albumin-bound

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + sirolimus albumin-bound

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sodium benzoate
  • Breyna (budesonide/ formoterol inhaled)
    +
    sodium benzoate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium benzoate

    monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylacetate
  • Breyna (budesonide/ formoterol inhaled)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium phenylacetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylbutyrate
  • Breyna (budesonide/ formoterol inhaled)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium phenylbutyrate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium polystyrene sulfonate
  • Breyna (budesonide/ formoterol inhaled)
    +
    sodium polystyrene sulfonate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium polystyrene sulfonate

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sodium thiosulfate
  • Breyna (budesonide/ formoterol inhaled)
    +
    sodium thiosulfate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium thiosulfate

    if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

  • solriamfetol
  • Breyna (budesonide/ formoterol inhaled)
    +
    solriamfetol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + solriamfetol

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • sorafenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • spironolactone
  • Breyna (budesonide/ formoterol inhaled)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sulfate bowel prep
  • Breyna (budesonide/ formoterol inhaled)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sulfate bowel prep

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sulindac
  • Breyna (budesonide/ formoterol inhaled)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sumatriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tacrolimus
  • Breyna (budesonide/ formoterol inhaled)
    +
    tacrolimus
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + tacrolimus

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + tacrolimus

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tafasitamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    tafasitamab
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + tafasitamab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + tafasitamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tagraxofusp
  • Breyna (budesonide/ formoterol inhaled)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • taletrectinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    taletrectinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + taletrectinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telavancin
  • Breyna (budesonide/ formoterol inhaled)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + telavancin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telmisartan
  • Breyna (budesonide/ formoterol inhaled)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terazosin
  • Breyna (budesonide/ formoterol inhaled)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Breyna (budesonide/ formoterol inhaled)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + terbutaline

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • teriflunomide
  • Breyna (budesonide/ formoterol inhaled)
    +
    teriflunomide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + teriflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + teriflunomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • testosterone
  • Breyna (budesonide/ formoterol inhaled)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tetrabenazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    tetrabenazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tetrabenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • theophylline
  • Breyna (budesonide/ formoterol inhaled)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + theophylline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • thyroid
  • Breyna (budesonide/ formoterol inhaled)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + thyroid

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • tivozanib
  • Breyna (budesonide/ formoterol inhaled)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • tolmetin
  • Breyna (budesonide/ formoterol inhaled)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • topiramate
  • Breyna (budesonide/ formoterol inhaled)
    +
    topiramate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + topiramate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • torsemide
  • Breyna (budesonide/ formoterol inhaled)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + torsemide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • tramadol
  • Breyna (budesonide/ formoterol inhaled)
    +
    tramadol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tramadol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trametinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • trandolapril
  • Breyna (budesonide/ formoterol inhaled)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tranylcypromine
  • Breyna (budesonide/ formoterol inhaled)
    +
    tranylcypromine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tranylcypromine

    monitor BP, HR during and x2wk after tranylcypromine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • triamcinolone
  • Breyna (budesonide/ formoterol inhaled)
    +
    triamcinolone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + triamcinolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

    Caution Advised

    budesonide inhaled + triamcinolone

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • triamterene
  • Breyna (budesonide/ formoterol inhaled)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triclabendazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    triclabendazole
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triclabendazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trifluridine
  • Breyna (budesonide/ formoterol inhaled)
    +
    trifluridine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trifluridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trimipramine
  • Breyna (budesonide/ formoterol inhaled)
    +
    trimipramine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trimipramine

    monitor BP, HR during and x2wk after trimipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • triptorelin
  • Breyna (budesonide/ formoterol inhaled)
    +
    triptorelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triptorelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • trospium
  • Breyna (budesonide/ formoterol inhaled)
    +
    trospium
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trospium

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • ubrogepant
  • Breyna (budesonide/ formoterol inhaled)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ubrogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vadadustat
  • Breyna (budesonide/ formoterol inhaled)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vadadustat

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • valsartan
  • Breyna (budesonide/ formoterol inhaled)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vamorolone
  • Breyna (budesonide/ formoterol inhaled)
    +
    vamorolone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + vamorolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

    Caution Advised

    budesonide inhaled + vamorolone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vasopressin
  • Breyna (budesonide/ formoterol inhaled)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vemurafenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    vemurafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vemurafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • venlafaxine
  • Breyna (budesonide/ formoterol inhaled)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • verapamil
  • Breyna (budesonide/ formoterol inhaled)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + verapamil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • viloxazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    viloxazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + viloxazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • voclosporin
  • Breyna (budesonide/ formoterol inhaled)
    +
    voclosporin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    budesonide inhaled + voclosporin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • yohimbe
  • Breyna (budesonide/ formoterol inhaled)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + yohimbe

    monitor BP, HR during and x2wk after yohimbe D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • zavegepant
  • Breyna (budesonide/ formoterol inhaled)
    +
    zavegepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ziftomenib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ziftomenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ziftomenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ziv-aflibercept
  • Breyna (budesonide/ formoterol inhaled)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zolmitriptan
  • Breyna (budesonide/ formoterol inhaled)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + zolmitriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zonisamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + zonisamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Caution Advised

  • abatacept
  • Breyna (budesonide/ formoterol inhaled)
    +
    abatacept
    1 interaction

    Caution Advised

    budesonide inhaled + abatacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • abemaciclib
  • Breyna (budesonide/ formoterol inhaled)
    +
    abemaciclib
    1 interaction

    Caution Advised

    budesonide inhaled + abemaciclib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • abrocitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    abrocitinib
    1 interaction

    Caution Advised

    budesonide inhaled + abrocitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • acalabrutinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    acalabrutinib
    1 interaction

    Caution Advised

    budesonide inhaled + acalabrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • adalimumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    adalimumab
    1 interaction

    Caution Advised

    budesonide inhaled + adalimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • afamitresgene autoleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    afamitresgene autoleucel
    1 interaction

    Caution Advised

    budesonide inhaled + afamitresgene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • aldesleukin
  • Breyna (budesonide/ formoterol inhaled)
    +
    aldesleukin
    1 interaction

    Caution Advised

    budesonide inhaled + aldesleukin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • alemtuzumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    alemtuzumab
    1 interaction

    Caution Advised

    budesonide inhaled + alemtuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • anakinra
  • Breyna (budesonide/ formoterol inhaled)
    +
    anakinra
    1 interaction

    Caution Advised

    budesonide inhaled + anakinra

    caution advised: combo may incr. risk of serious infection (additive effects)

  • anifrolumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    anifrolumab
    1 interaction

    Caution Advised

    budesonide inhaled + anifrolumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • anti-thymocyte globulin
  • Breyna (budesonide/ formoterol inhaled)
    +
    anti-thymocyte globulin
    1 interaction

    Caution Advised

    budesonide inhaled + anti-thymocyte globulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • atazanavir
  • Breyna (budesonide/ formoterol inhaled)
    +
    atazanavir
    1 interaction

    Caution Advised

    budesonide inhaled + atazanavir

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • atidarsagene autotemcel
  • Breyna (budesonide/ formoterol inhaled)
    +
    atidarsagene autotemcel
    1 interaction

    Caution Advised

    budesonide inhaled + atidarsagene autotemcel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • avacopan
  • Breyna (budesonide/ formoterol inhaled)
    +
    avacopan
    1 interaction

    Caution Advised

    budesonide inhaled + avacopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • axicabtagene ciloleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    axicabtagene ciloleucel
    1 interaction

    Caution Advised

    budesonide inhaled + axicabtagene ciloleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • azacitidine
  • Breyna (budesonide/ formoterol inhaled)
    +
    azacitidine
    1 interaction

    Caution Advised

    budesonide inhaled + azacitidine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • azathioprine
  • Breyna (budesonide/ formoterol inhaled)
    +
    azathioprine
    1 interaction

    Caution Advised

    budesonide inhaled + azathioprine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • baricitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    baricitinib
    1 interaction

    Caution Advised

    budesonide inhaled + baricitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • basiliximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    basiliximab
    1 interaction

    Caution Advised

    budesonide inhaled + basiliximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • beclomethasone inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    beclomethasone inhaled
    1 interaction

    Caution Advised

    budesonide inhaled + beclomethasone inhaled

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • beclomethasone nasal
  • Breyna (budesonide/ formoterol inhaled)
    +
    beclomethasone nasal
    1 interaction

    Caution Advised

    budesonide inhaled + beclomethasone nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • belatacept
  • Breyna (budesonide/ formoterol inhaled)
    +
    belatacept
    1 interaction

    Caution Advised

    budesonide inhaled + belatacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belimumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    belimumab
    1 interaction

    Caution Advised

    budesonide inhaled + belimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belinostat
  • Breyna (budesonide/ formoterol inhaled)
    +
    belinostat
    1 interaction

    Caution Advised

    budesonide inhaled + belinostat

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bendamustine
  • Breyna (budesonide/ formoterol inhaled)
    +
    bendamustine
    1 interaction

    Caution Advised

    budesonide inhaled + bendamustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bimekizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    bimekizumab
    1 interaction

    Caution Advised

    budesonide inhaled + bimekizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • blinatumomab
  • Breyna (budesonide/ formoterol inhaled)
    +
    blinatumomab
    1 interaction

    Caution Advised

    budesonide inhaled + blinatumomab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bortezomib
  • Breyna (budesonide/ formoterol inhaled)
    +
    bortezomib
    1 interaction

    Caution Advised

    budesonide inhaled + bortezomib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brentuximab vedotin
  • Breyna (budesonide/ formoterol inhaled)
    +
    brentuximab vedotin
    1 interaction

    Caution Advised

    budesonide inhaled + brentuximab vedotin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brexucabtagene autoleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    brexucabtagene autoleucel
    1 interaction

    Caution Advised

    budesonide inhaled + brexucabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brodalumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    brodalumab
    1 interaction

    Caution Advised

    budesonide inhaled + brodalumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • budesonide nasal
  • Breyna (budesonide/ formoterol inhaled)
    +
    budesonide nasal
    1 interaction

    Caution Advised

    budesonide inhaled + budesonide nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • budesonide rectal
  • Breyna (budesonide/ formoterol inhaled)
    +
    budesonide rectal
    1 interaction

    Caution Advised

    budesonide inhaled + budesonide rectal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • busulfan
  • Breyna (budesonide/ formoterol inhaled)
    +
    busulfan
    1 interaction

    Caution Advised

    budesonide inhaled + busulfan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cabazitaxel
  • Breyna (budesonide/ formoterol inhaled)
    +
    cabazitaxel
    1 interaction

    Caution Advised

    budesonide inhaled + cabazitaxel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • canakinumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    canakinumab
    1 interaction

    Caution Advised

    budesonide inhaled + canakinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • carboplatin
  • Breyna (budesonide/ formoterol inhaled)
    +
    carboplatin
    1 interaction

    Caution Advised

    budesonide inhaled + carboplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • carmustine
  • Breyna (budesonide/ formoterol inhaled)
    +
    carmustine
    1 interaction

    Caution Advised

    budesonide inhaled + carmustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • certolizumab pegol
  • Breyna (budesonide/ formoterol inhaled)
    +
    certolizumab pegol
    1 interaction

    Caution Advised

    budesonide inhaled + certolizumab pegol

    caution advised: combo may incr. risk of serious infection (additive effects)

  • chlorambucil
  • Breyna (budesonide/ formoterol inhaled)
    +
    chlorambucil
    1 interaction

    Caution Advised

    budesonide inhaled + chlorambucil

    caution advised: combo may incr. risk of serious infection (additive effects)

  • chloramphenicol
  • Breyna (budesonide/ formoterol inhaled)
    +
    chloramphenicol
    1 interaction

    Caution Advised

    budesonide inhaled + chloramphenicol

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • ciltacabtagene autoleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    ciltacabtagene autoleucel
    1 interaction

    Caution Advised

    budesonide inhaled + ciltacabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cladribine injection
  • Breyna (budesonide/ formoterol inhaled)
    +
    cladribine injection
    1 interaction

    Caution Advised

    budesonide inhaled + cladribine injection

    caution advised: combo may incr. risk of serious infection (additive effects)

  • clobetasol ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    clobetasol ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + clobetasol ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • clofarabine
  • Breyna (budesonide/ formoterol inhaled)
    +
    clofarabine
    1 interaction

    Caution Advised

    budesonide inhaled + clofarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • crovalimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    crovalimab
    1 interaction

    Caution Advised

    budesonide inhaled + crovalimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cyclophosphamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    cyclophosphamide
    1 interaction

    Caution Advised

    budesonide inhaled + cyclophosphamide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cytarabine
  • Breyna (budesonide/ formoterol inhaled)
    +
    cytarabine
    1 interaction

    Caution Advised

    budesonide inhaled + cytarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dactinomycin
  • Breyna (budesonide/ formoterol inhaled)
    +
    dactinomycin
    1 interaction

    Caution Advised

    budesonide inhaled + dactinomycin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • danicopan
  • Breyna (budesonide/ formoterol inhaled)
    +
    danicopan
    1 interaction

    Caution Advised

    budesonide inhaled + danicopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • daratumumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    daratumumab
    1 interaction

    Caution Advised

    budesonide inhaled + daratumumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • daunorubicin
  • Breyna (budesonide/ formoterol inhaled)
    +
    daunorubicin
    1 interaction

    Caution Advised

    budesonide inhaled + daunorubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • delgocitinib topical
  • Breyna (budesonide/ formoterol inhaled)
    +
    delgocitinib topical
    1 interaction

    Caution Advised

    budesonide inhaled + delgocitinib topical

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deucravacitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    deucravacitinib
    1 interaction

    Caution Advised

    budesonide inhaled + deucravacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deuruxolitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    deuruxolitinib
    1 interaction

    Caution Advised

    budesonide inhaled + deuruxolitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dexamethasone ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    dexamethasone ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + dexamethasone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • difluprednate ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    difluprednate ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + difluprednate ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • dimethyl fumarate
  • Breyna (budesonide/ formoterol inhaled)
    +
    dimethyl fumarate
    1 interaction

    Caution Advised

    budesonide inhaled + dimethyl fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • diroximel fumarate
  • Breyna (budesonide/ formoterol inhaled)
    +
    diroximel fumarate
    1 interaction

    Caution Advised

    budesonide inhaled + diroximel fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • docetaxel
  • Breyna (budesonide/ formoterol inhaled)
    +
    docetaxel
    1 interaction

    Caution Advised

    budesonide inhaled + docetaxel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • doxorubicin
  • Breyna (budesonide/ formoterol inhaled)
    +
    doxorubicin
    1 interaction

    Caution Advised

    budesonide inhaled + doxorubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dupilumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    dupilumab
    1 interaction

    Caution Advised

    budesonide inhaled + dupilumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • duvelisib
  • Breyna (budesonide/ formoterol inhaled)
    +
    duvelisib
    1 interaction

    Caution Advised

    budesonide inhaled + duvelisib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • eculizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    eculizumab
    1 interaction

    Caution Advised

    budesonide inhaled + eculizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • efgartigimod alfa
  • Breyna (budesonide/ formoterol inhaled)
    +
    efgartigimod alfa
    1 interaction

    Caution Advised

    budesonide inhaled + efgartigimod alfa

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elivaldogene autotemcel
  • Breyna (budesonide/ formoterol inhaled)
    +
    elivaldogene autotemcel
    1 interaction

    Caution Advised

    budesonide inhaled + elivaldogene autotemcel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elotuzumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    elotuzumab
    1 interaction

    Caution Advised

    budesonide inhaled + elotuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elranatamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    elranatamab
    1 interaction

    Caution Advised

    budesonide inhaled + elranatamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • epcoritamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    epcoritamab
    1 interaction

    Caution Advised

    budesonide inhaled + epcoritamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • etanercept
  • Breyna (budesonide/ formoterol inhaled)
    +
    etanercept
    1 interaction

    Caution Advised

    budesonide inhaled + etanercept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • etoposide
  • Breyna (budesonide/ formoterol inhaled)
    +
    etoposide
    1 interaction

    Caution Advised

    budesonide inhaled + etoposide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • etuvetidigene autotemcel
  • Breyna (budesonide/ formoterol inhaled)
    +
    etuvetidigene autotemcel
    1 interaction

    Caution Advised

    budesonide inhaled + etuvetidigene autotemcel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • floxuridine
  • Breyna (budesonide/ formoterol inhaled)
    +
    floxuridine
    1 interaction

    Caution Advised

    budesonide inhaled + floxuridine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fludarabine
  • Breyna (budesonide/ formoterol inhaled)
    +
    fludarabine
    1 interaction

    Caution Advised

    budesonide inhaled + fludarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • flunisolide nasal
  • Breyna (budesonide/ formoterol inhaled)
    +
    flunisolide nasal
    1 interaction

    Caution Advised

    budesonide inhaled + flunisolide nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluocinolone intravitreal
  • Breyna (budesonide/ formoterol inhaled)
    +
    fluocinolone intravitreal
    1 interaction

    Caution Advised

    budesonide inhaled + fluocinolone intravitreal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluorometholone ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    fluorometholone ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + fluorometholone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • fluticasone furoate
  • Breyna (budesonide/ formoterol inhaled)
    +
    fluticasone furoate
    1 interaction

    Caution Advised

    budesonide inhaled + fluticasone furoate

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • fluticasone propionate
  • Breyna (budesonide/ formoterol inhaled)
    +
    fluticasone propionate
    1 interaction

    Caution Advised

    budesonide inhaled + fluticasone propionate

    caution advised: combo may incr. risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • gemtuzumab ozogamicin
  • Breyna (budesonide/ formoterol inhaled)
    +
    gemtuzumab ozogamicin
    1 interaction

    Caution Advised

    budesonide inhaled + gemtuzumab ozogamicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • glofitamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    glofitamab
    1 interaction

    Caution Advised

    budesonide inhaled + glofitamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • golimumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    golimumab
    1 interaction

    Caution Advised

    budesonide inhaled + golimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • guselkumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    guselkumab
    1 interaction

    Caution Advised

    budesonide inhaled + guselkumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • hydrocortisone ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydrocortisone ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + hydrocortisone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • hydroxyurea
  • Breyna (budesonide/ formoterol inhaled)
    +
    hydroxyurea
    1 interaction

    Caution Advised

    budesonide inhaled + hydroxyurea

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ibritumomab tiuxetan
  • Breyna (budesonide/ formoterol inhaled)
    +
    ibritumomab tiuxetan
    1 interaction

    Caution Advised

    budesonide inhaled + ibritumomab tiuxetan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • icotrokinra
  • Breyna (budesonide/ formoterol inhaled)
    +
    icotrokinra
    1 interaction

    Caution Advised

    budesonide inhaled + icotrokinra

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idarubicin
  • Breyna (budesonide/ formoterol inhaled)
    +
    idarubicin
    1 interaction

    Caution Advised

    budesonide inhaled + idarubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idecabtagene vicleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    idecabtagene vicleucel
    1 interaction

    Caution Advised

    budesonide inhaled + idecabtagene vicleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idelalisib
  • Breyna (budesonide/ formoterol inhaled)
    +
    idelalisib
    1 interaction

    Caution Advised

    budesonide inhaled + idelalisib

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ifosfamide
  • Breyna (budesonide/ formoterol inhaled)
    +
    ifosfamide
    1 interaction

    Caution Advised

    budesonide inhaled + ifosfamide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • inebilizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    inebilizumab
    1 interaction

    Caution Advised

    budesonide inhaled + inebilizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • infliximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    infliximab
    1 interaction

    Caution Advised

    budesonide inhaled + infliximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • iptacopan
  • Breyna (budesonide/ formoterol inhaled)
    +
    iptacopan
    1 interaction

    Caution Advised

    budesonide inhaled + iptacopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • irinotecan
  • Breyna (budesonide/ formoterol inhaled)
    +
    irinotecan
    1 interaction

    Caution Advised

    budesonide inhaled + irinotecan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • isatuximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    isatuximab
    1 interaction

    Caution Advised

    budesonide inhaled + isatuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • itraconazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    itraconazole
    1 interaction

    Caution Advised

    budesonide inhaled + itraconazole

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • ixabepilone
  • Breyna (budesonide/ formoterol inhaled)
    +
    ixabepilone
    1 interaction

    Caution Advised

    budesonide inhaled + ixabepilone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ixekizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ixekizumab
    1 interaction

    Caution Advised

    budesonide inhaled + ixekizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ketoconazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    ketoconazole
    1 interaction

    Caution Advised

    budesonide inhaled + ketoconazole

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • lebrikizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    lebrikizumab
    1 interaction

    Caution Advised

    budesonide inhaled + lebrikizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • linvoseltamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    linvoseltamab
    1 interaction

    Caution Advised

    budesonide inhaled + linvoseltamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lisocabtagene maraleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    lisocabtagene maraleucel
    1 interaction

    Caution Advised

    budesonide inhaled + lisocabtagene maraleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lomustine
  • Breyna (budesonide/ formoterol inhaled)
    +
    lomustine
    1 interaction

    Caution Advised

    budesonide inhaled + lomustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • loncastuximab tesirine
  • Breyna (budesonide/ formoterol inhaled)
    +
    loncastuximab tesirine
    1 interaction

    Caution Advised

    budesonide inhaled + loncastuximab tesirine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • loteprednol ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    loteprednol ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + loteprednol ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Breyna (budesonide/ formoterol inhaled)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Caution Advised

    budesonide inhaled + lymphocyte immune globulin, anti-thymocyte globulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • melphalan
  • Breyna (budesonide/ formoterol inhaled)
    +
    melphalan
    1 interaction

    Caution Advised

    budesonide inhaled + melphalan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mercaptopurine
  • Breyna (budesonide/ formoterol inhaled)
    +
    mercaptopurine
    1 interaction

    Caution Advised

    budesonide inhaled + mercaptopurine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • methotrexate
  • Breyna (budesonide/ formoterol inhaled)
    +
    methotrexate
    1 interaction

    Caution Advised

    budesonide inhaled + methotrexate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mirikizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    mirikizumab
    1 interaction

    Caution Advised

    budesonide inhaled + mirikizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mitoxantrone
  • Breyna (budesonide/ formoterol inhaled)
    +
    mitoxantrone
    1 interaction

    Caution Advised

    budesonide inhaled + mitoxantrone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mogamulizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    mogamulizumab
    1 interaction

    Caution Advised

    budesonide inhaled + mogamulizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • momelotinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    momelotinib
    1 interaction

    Caution Advised

    budesonide inhaled + momelotinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mometasone implant
  • Breyna (budesonide/ formoterol inhaled)
    +
    mometasone implant
    1 interaction

    Caution Advised

    budesonide inhaled + mometasone implant

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • mometasone inhaled
  • Breyna (budesonide/ formoterol inhaled)
    +
    mometasone inhaled
    1 interaction

    Caution Advised

    budesonide inhaled + mometasone inhaled

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • mometasone nasal
  • Breyna (budesonide/ formoterol inhaled)
    +
    mometasone nasal
    1 interaction

    Caution Advised

    budesonide inhaled + mometasone nasal

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate corticosteroid tx)

  • monomethyl fumarate
  • Breyna (budesonide/ formoterol inhaled)
    +
    monomethyl fumarate
    1 interaction

    Caution Advised

    budesonide inhaled + monomethyl fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mosunetuzumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    mosunetuzumab
    1 interaction

    Caution Advised

    budesonide inhaled + mosunetuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mycophenolate mofetil
  • Breyna (budesonide/ formoterol inhaled)
    +
    mycophenolate mofetil
    1 interaction

    Caution Advised

    budesonide inhaled + mycophenolate mofetil

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mycophenolic acid
  • Breyna (budesonide/ formoterol inhaled)
    +
    mycophenolic acid
    1 interaction

    Caution Advised

    budesonide inhaled + mycophenolic acid

    caution advised: combo may incr. risk of serious infection (additive effects)

  • narsoplimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    narsoplimab
    1 interaction

    Caution Advised

    budesonide inhaled + narsoplimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • nefazodone
  • Breyna (budesonide/ formoterol inhaled)
    +
    nefazodone
    1 interaction

    Caution Advised

    budesonide inhaled + nefazodone

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • nelarabine
  • Breyna (budesonide/ formoterol inhaled)
    +
    nelarabine
    1 interaction

    Caution Advised

    budesonide inhaled + nelarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • nelfinavir
  • Breyna (budesonide/ formoterol inhaled)
    +
    nelfinavir
    1 interaction

    Caution Advised

    budesonide inhaled + nelfinavir

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • nipocalimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    nipocalimab
    1 interaction

    Caution Advised

    budesonide inhaled + nipocalimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • obecabtagene autoleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    obecabtagene autoleucel
    1 interaction

    Caution Advised

    budesonide inhaled + obecabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ocrelizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ocrelizumab
    1 interaction

    Caution Advised

    budesonide inhaled + ocrelizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ofatumumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ofatumumab
    1 interaction

    Caution Advised

    budesonide inhaled + ofatumumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • oxaliplatin
  • Breyna (budesonide/ formoterol inhaled)
    +
    oxaliplatin
    1 interaction

    Caution Advised

    budesonide inhaled + oxaliplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • paclitaxel
  • Breyna (budesonide/ formoterol inhaled)
    +
    paclitaxel
    1 interaction

    Caution Advised

    budesonide inhaled + paclitaxel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pegcetacoplan
  • Breyna (budesonide/ formoterol inhaled)
    +
    pegcetacoplan
    1 interaction

    Caution Advised

    budesonide inhaled + pegcetacoplan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pentostatin
  • Breyna (budesonide/ formoterol inhaled)
    +
    pentostatin
    1 interaction

    Caution Advised

    budesonide inhaled + pentostatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pirtobrutinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    pirtobrutinib
    1 interaction

    Caution Advised

    budesonide inhaled + pirtobrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • polatuzumab vedotin
  • Breyna (budesonide/ formoterol inhaled)
    +
    polatuzumab vedotin
    1 interaction

    Caution Advised

    budesonide inhaled + polatuzumab vedotin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pomalidomide
  • Breyna (budesonide/ formoterol inhaled)
    +
    pomalidomide
    1 interaction

    Caution Advised

    budesonide inhaled + pomalidomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pozelimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    pozelimab
    1 interaction

    Caution Advised

    budesonide inhaled + pozelimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • prednisolone ophthalmic
  • Breyna (budesonide/ formoterol inhaled)
    +
    prednisolone ophthalmic
    1 interaction

    Caution Advised

    budesonide inhaled + prednisolone ophthalmic

    caution advised: combo may incr. risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (additive effects, duplicate therapy)

  • ravulizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ravulizumab
    1 interaction

    Caution Advised

    budesonide inhaled + ravulizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rilonacept
  • Breyna (budesonide/ formoterol inhaled)
    +
    rilonacept
    1 interaction

    Caution Advised

    budesonide inhaled + rilonacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rilzabrutinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    rilzabrutinib
    1 interaction

    Caution Advised

    budesonide inhaled + rilzabrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • risankizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    risankizumab
    1 interaction

    Caution Advised

    budesonide inhaled + risankizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ritlecitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ritlecitinib
    1 interaction

    Caution Advised

    budesonide inhaled + ritlecitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rituximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    rituximab
    1 interaction

    Caution Advised

    budesonide inhaled + rituximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ropeginterferon alfa-2b
  • Breyna (budesonide/ formoterol inhaled)
    +
    ropeginterferon alfa-2b
    1 interaction

    Caution Advised

    budesonide inhaled + ropeginterferon alfa-2b

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rozanolixizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    rozanolixizumab
    1 interaction

    Caution Advised

    budesonide inhaled + rozanolixizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ruxolitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    ruxolitinib
    1 interaction

    Caution Advised

    budesonide inhaled + ruxolitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ruxolitinib topical
  • Breyna (budesonide/ formoterol inhaled)
    +
    ruxolitinib topical
    1 interaction

    Caution Advised

    budesonide inhaled + ruxolitinib topical

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sarilumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    sarilumab
    1 interaction

    Caution Advised

    budesonide inhaled + sarilumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • satralizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    satralizumab
    1 interaction

    Caution Advised

    budesonide inhaled + satralizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • secukinumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    secukinumab
    1 interaction

    Caution Advised

    budesonide inhaled + secukinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sibeprenlimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    sibeprenlimab
    1 interaction

    Caution Advised

    budesonide inhaled + sibeprenlimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • siltuximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    siltuximab
    1 interaction

    Caution Advised

    budesonide inhaled + siltuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sirolimus
  • Breyna (budesonide/ formoterol inhaled)
    +
    sirolimus
    1 interaction

    Caution Advised

    budesonide inhaled + sirolimus

    caution advised: combo may incr. risk of serious infection (additive effects)

  • spesolimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    spesolimab
    1 interaction

    Caution Advised

    budesonide inhaled + spesolimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sulfasalazine
  • Breyna (budesonide/ formoterol inhaled)
    +
    sulfasalazine
    1 interaction

    Caution Advised

    budesonide inhaled + sulfasalazine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sutimlimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    sutimlimab
    1 interaction

    Caution Advised

    budesonide inhaled + sutimlimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • talquetamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    talquetamab
    1 interaction

    Caution Advised

    budesonide inhaled + talquetamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tarlatamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    tarlatamab
    1 interaction

    Caution Advised

    budesonide inhaled + tarlatamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • teclistamab
  • Breyna (budesonide/ formoterol inhaled)
    +
    teclistamab
    1 interaction

    Caution Advised

    budesonide inhaled + teclistamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • temozolomide
  • Breyna (budesonide/ formoterol inhaled)
    +
    temozolomide
    1 interaction

    Caution Advised

    budesonide inhaled + temozolomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • temsirolimus
  • Breyna (budesonide/ formoterol inhaled)
    +
    temsirolimus
    1 interaction

    Caution Advised

    budesonide inhaled + temsirolimus

    caution advised: combo may incr. risk of serious infection (additive effects)

  • teplizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    teplizumab
    1 interaction

    Caution Advised

    budesonide inhaled + teplizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • thioguanine
  • Breyna (budesonide/ formoterol inhaled)
    +
    thioguanine
    1 interaction

    Caution Advised

    budesonide inhaled + thioguanine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • thiotepa
  • Breyna (budesonide/ formoterol inhaled)
    +
    thiotepa
    1 interaction

    Caution Advised

    budesonide inhaled + thiotepa

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tildrakizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    tildrakizumab
    1 interaction

    Caution Advised

    budesonide inhaled + tildrakizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tipranavir
  • Breyna (budesonide/ formoterol inhaled)
    +
    tipranavir
    1 interaction

    Caution Advised

    budesonide inhaled + tipranavir

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • tisagenlecleucel
  • Breyna (budesonide/ formoterol inhaled)
    +
    tisagenlecleucel
    1 interaction

    Caution Advised

    budesonide inhaled + tisagenlecleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tocilizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    tocilizumab
    1 interaction

    Caution Advised

    budesonide inhaled + tocilizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tofacitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    tofacitinib
    1 interaction

    Caution Advised

    budesonide inhaled + tofacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • topotecan
  • Breyna (budesonide/ formoterol inhaled)
    +
    topotecan
    1 interaction

    Caution Advised

    budesonide inhaled + topotecan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • trabectedin
  • Breyna (budesonide/ formoterol inhaled)
    +
    trabectedin
    1 interaction

    Caution Advised

    budesonide inhaled + trabectedin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tralokinumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    tralokinumab
    1 interaction

    Caution Advised

    budesonide inhaled + tralokinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tucatinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    tucatinib
    1 interaction

    Caution Advised

    budesonide inhaled + tucatinib

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • ublituximab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ublituximab
    1 interaction

    Caution Advised

    budesonide inhaled + ublituximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • upadacitinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    upadacitinib
    1 interaction

    Caution Advised

    budesonide inhaled + upadacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ustekinumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    ustekinumab
    1 interaction

    Caution Advised

    budesonide inhaled + ustekinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vedolizumab
  • Breyna (budesonide/ formoterol inhaled)
    +
    vedolizumab
    1 interaction

    Caution Advised

    budesonide inhaled + vedolizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • venetoclax
  • Breyna (budesonide/ formoterol inhaled)
    +
    venetoclax
    1 interaction

    Caution Advised

    budesonide inhaled + venetoclax

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vilobelimab
  • Breyna (budesonide/ formoterol inhaled)
    +
    vilobelimab
    1 interaction

    Caution Advised

    budesonide inhaled + vilobelimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vinblastine
  • Breyna (budesonide/ formoterol inhaled)
    +
    vinblastine
    1 interaction

    Caution Advised

    budesonide inhaled + vinblastine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vincristine
  • Breyna (budesonide/ formoterol inhaled)
    +
    vincristine
    1 interaction

    Caution Advised

    budesonide inhaled + vincristine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vinorelbine
  • Breyna (budesonide/ formoterol inhaled)
    +
    vinorelbine
    1 interaction

    Caution Advised

    budesonide inhaled + vinorelbine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • voriconazole
  • Breyna (budesonide/ formoterol inhaled)
    +
    voriconazole
    1 interaction

    Caution Advised

    budesonide inhaled + voriconazole

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • zanubrutinib
  • Breyna (budesonide/ formoterol inhaled)
    +
    zanubrutinib
    1 interaction

    Caution Advised

    budesonide inhaled + zanubrutinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • zilucoplan
  • Breyna (budesonide/ formoterol inhaled)
    +
    zilucoplan
    1 interaction

    Caution Advised

    budesonide inhaled + zilucoplan

    caution advised: combo may incr. risk of serious infection (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@e024f77
  • bronchospasm, paradoxical
  • asthma exacerbation
  • hypersensitivity reaction
  • anaphylaxis
  • HTN
  • angina
  • arrhythmia
  • hypokalemia
  • hyperglycemia
  • eosinophilia
  • Churg-Strauss syndrome
  • adrenal suppression (long-term use)
  • hypercorticism (long-term use)
  • immunosuppression (long-term use)
  • glaucoma (long-term use)
  • cataracts (long-term use)
  • osteoporosis (long-term use)
  • growth suppression (long-term use in peds patients)

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@13298864
  • nasopharyngitis
  • headache
  • URI symptoms
  • pharyngolaryngeal pain
  • sinusitis
  • influenza
  • back pain
  • nasal congestion
  • dyspepsia
  • nausea
  • vomiting
  • candidiasis, oral
  • BP changes
  • chest pain
  • palpitations
  • tachycardia
  • muscle cramps
  • tremor
  • nervousness
  • insomnia
  • cough
  • bronchitis
  • respiratory infection

Safety/Monitoring .

Monitoring Parameters
BMD at baseline if osteoporosis risk factors or COPD, then periodically; height in children/adolescents; oral cavity exam periodically; consider ophthalmic exam if long-term use, change in vision, IOP/glaucoma/cataracts history

Pregnancy/Lactation .

Pregnancy

Clinical Summary

budesonide inhaled: may use during pregnancy; drug of choice for asthma use during pregnancy; risk of teratogenicity low based on human data

formoterol inhaled: weigh risk/benefit during pregnancy, especially during labor and delivery; inadequate human data available; risk of fetal harm low, though possible risk of delayed ossification based on animal data at 50x MRHD; risk of interference with uterine contractility based on drug's mechanism of action

Lactation

Clinical Summary

budesonide inhaled: may use while breastfeeding; no known risk of infant harm based on human data and minimal drug excretion into milk; no human data available to assess effects on milk production

formoterol inhaled: may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal systemic absorption in breastfeeding patients; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@2f2ea6ea

Metabolism: for budesonide: liver extensively; CYP450: 3A4 substrate; for formoterol: liver extensively; CYP450: 2A6, 2C9/19, 2D6 substrate; UGT: 1A1, 1A8, 1A9, 2B7, 2B15 substrate; Info: minimal systemic absorption

Excretion: for budesonide: urine 60% (none unchanged), feces; Half-life: 4.7h; for formoterol: urine 62%, feces 24%; Half-life: 7h

Subclass: Beta-2 Agonists, Inhaled Long-Acting (LABAs) ; Corticosteroids, Inhaled

Mechanism of Action
for budesonide: exact mechanism of anti-inflammatory action unknown; inhibits multiple inflammatory cytokines; produces multiple glucocorticoid and mineralocorticoid effects; for formoterol: selectively stimulates beta-2 adrenergic receptors, relaxing airway smooth muscle

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Mylan Pharmaceuticals, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@17ab92ae

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information